0.9281
Precedente Chiudi:
$0.8815
Aprire:
$0.89
Volume 24 ore:
470.93K
Relative Volume:
0.08
Capitalizzazione di mercato:
$45.11M
Reddito:
$1.14M
Utile/perdita netta:
$-56.27M
Rapporto P/E:
-0.7646
EPS:
-1.2139
Flusso di cassa netto:
$-51.94M
1 W Prestazione:
-3.31%
1M Prestazione:
-7.03%
6M Prestazione:
-8.11%
1 anno Prestazione:
-51.66%
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Nome
Werewolf Therapeutics Inc
Settore
Industria
Telefono
617-952-0555
Indirizzo
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
HOWL
Werewolf Therapeutics Inc
|
0.9281 | 46.65M | 1.14M | -56.27M | -51.94M | -1.2139 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-04-03 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-24 | Iniziato | Wedbush | Outperform |
| 2023-06-06 | Ripresa | Jefferies | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-25 | Iniziato | Evercore ISI | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-25 | Iniziato | Jefferies | Buy |
| 2021-05-25 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie
HOWL Forecast — Price Target — Prediction for 2027 - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - The Daily Tribune News
Ambros deal would give Werewolf (NASDAQ: HOWL) investors rights to future sales of legacy drug assets - Stock Titan
Werewolf Therapeutics | SCHEDULE 13G: Others - Moomoo
German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
HOWL Q2 2026 Earnings: Werewolf Therapeutics Swings to Surprise Profit, Topping EPS Estimate by 130%Operating Margin Analysis - dars.gov.et
Werewolf Therapeutics stock steadies as investors weigh recent losses and biotech outlook - AD HOC NEWS
Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers - TipRanks
Werewolf Therapeutics (HOWL) Dips 1.43% to $0.97 as Tight Trading Range Sends Stock Toward Key SupportEarnings Miss Risk - dars.gov.et
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
HOWL|Werewolf Therapeutics Inc|Price:0.980|Chg%:+0.014 - TradingKey
Werewolf Therapeutics Stock Price Forecast. Should You Buy HOWL? - StockInvest.us
Werewolf Therapeutics stock gains on merger scrutiny and trial progress - ad-hoc-news.de
HOWL Q2 2026 Earnings: 130% EPS Surprise vs. a 5.46% SelloffPreliminary Results - dars.gov.et
HOWL Q2 2026 Earnings: EPS Beats Estimates by 130%, Shares Edge Down 2.87%Earnings Volatility Report - dars.gov.et
1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost - Yahoo Finance
3 Firms Build Biotech Merger With $150M In Private Funding - Law360
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Werewolf (HOWL) Outlook: Moves 102.57% Up to $0.87 in the Latest Reading; Boundary Watch: $0.83 and $0.91 Define the Nearby Reference Levels at the CloseMoving Average Ribbon - vinanet.vn
HOWL | Werewolf Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Werewolf and Ambros Therapeutics announce merger - The Pharma Letter
Werewolf Therapeutics (NASDAQ:HOWL) Deal Changes Pipeline Focus - Kalkine Media
Werewolf Therapeutics Shares Surge Twofold After Ambros Merger, Investors Retain 6.8% Stake - TechStock²
Latham Watkins Advises on Oversubscribed Private Placement in Werewolf Ambros Merger Transaction - Latham & Watkins LLP
Werewolf Therapeutics, Inc. announced that it expects to receive $150 million in funding - marketscreener.com
Werewolf Therapeutics Strikes Reverse Merger With Ambros, Secures $150 Million for Rare Pain Drug - finance.biggo.com
Trending Stocks Today | Werewolf Therapeutics Shoots up 117.27% - Moomoo
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Watertown biotech agrees to reverse merger with Vivek Ramaswamy-backed startup - The Business Journals
Gold Moves Higher; US Composite PMI Surges In August - Benzinga
Werewolf Therapeutics (HOWL) Stock Soars 127% on Ambros Merger and $150M Financing Deal - Blockonomi
Werewolf Therapeutics stock soars on Ambros merger deal and $150 million PIPE - Quiver Quantitative
Why is Werewolf Therapeutics stock surging more than 100% today? By Investing.com - Investing.com Canada
Ambros Therapeutics to merge with Werewolf Therapeutics in all-stock deal - Dealroom
Why is Werewolf Therapeutics stock surging more than 100% today? - Investing.com
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug - Fierce Biotech
Why Is Werewolf Therapeutics Stock Gaining Friday?Werewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Israel Englander's HOWL Stock Soars on $500M DealWerewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Werewolf Therapeutics to Merge and Rebrand as Ambros - TipRanks
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing - Yahoo Finance
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future - StocksToTrade
Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today? - TipRanks
Werewolf (NASDAQ: HOWL) Ambros deal leaves holders with single-digit stake - Stock Titan
Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE, Holders Locked Up - TradingView
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement - Investing News Network
Werewolf Therapeutics stock soars 120% on Ambros merger deal - Investing.com
HOWL Stock Jumps As One-Off Deal Reshapes Outlook - StocksToTrade
HOWL Stock Jumps As One-Time Deal Fuels Q2 Profit - timothysykes.com
Werewolf Therapeutics to merge with Ambros in $150m deal - Investing.com
Werewolf Therapeutics, Ambros Therapeutics Plan Merger With $150 Million Financing - citybiz
Werewolf Therapeutics Inc Azioni (HOWL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Werewolf Therapeutics Inc Azioni (HOWL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
Jul 06 '26 |
Sale |
0.32 |
35,770 |
11,446 |
107,429 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):